The Crosstalk Between the RNA Demethylase, Non-Coding RNAs, and Transcription Factors in Gastric Cancer: an ALKBH5 Perspective
Fuda Xie,Bonan Chen,Alvin H. K. Cheung,Jun Yu,Ka Fai To,Wei Kang
DOI: https://doi.org/10.1002/ctd2.189
2023-01-01
Clinical and Translational Discovery
Abstract:Gastric cancer (GC) is the fifth most frequently diagnosed cancer worldwide and one of the leading causes of cancer-related deaths.1 Over one million (1 089 103) new cases of GC were diagnosed in 2020, which led to 768 793 deaths.2 The molecular classification of GC is complicated but well-articulated. The most applied histopathological classification was proposed by P. Lauren with three main subtypes: intestinal, diffuse, and mixed.3 The Cancer Genome Atlas research network has identified four subtypes by characteristic molecular abnormalities: Epstein-Barr virus positive, microsatellite instability-high, genomically stable, and tumors with chromosomal instability.4 Treatments for GC are comparatively inclusive and effective.2 Although extensive molecular mechanisms have been elucidated in the biological processes in GC prognosis, there are still challenges in the diagnosis and treatment due to the unclearness of the multifarious participators involved in GC progression. Recent advances in genomics and transcriptomics have provided new insights into the aberrantly activated pathways in GC. In the recently published article in Clinical and Translational Medicine, Fang et al. demonstrated that the existence of ALKBH5, an RNA demethylase that is known to play a crucial role in the regulation of RNA stability and metabolism,5 accelerates GC progression by stabilizing the JAK1 mRNA and thus activating the oncogenic JAK1-STAT3 pathway. Meanwhile, LINC00659 initialed the m6 modification function of ALKBH5 in a YTHDF2-dependent manner.6 N6-methyladenosine (m6A) is a highly pervasive modification in mRNAs and noncoding RNAs which affects RNA splicing, translation, stability, and epigenetic modification.7 It is universally acknowledged that m6A RNA methylation is modulated by a series of epigenetic modulator enzymes termed “writers” (methyltransferase), “erasers” (demethylases), and “readers” (proteins). ALKBH5 (AlkB Homolog 5, RNA Demethylase) belongs to the Fe (II)/α-ketoglutarate-dependent dioxygenase family, which employs ferrous iron and oxygen to eliminate aliphatic hydrocarbons or heteroatom groups from diverse substrates, such as DNA, RNA, and proteins.8 As an RNA demethylase, ALKBH5 catalyzes the process of m6A erasure, which is an essential post-transcriptional regulatory modification in eukaryotic mRNAs.9 Due to the modification effects of the mRNAs of canonical oncogenes, ALKBH5 has been recognized as a significant regulator in gastrointestinal carcinogenesis (Table 1). The predominant functions of ALKBH5 include the regulation of cellular responses to hypoxia, expression of transcription factors and non-coding RNAs, and aberrant epigenetic modifications.5 To add up, the ALKBH5-PD-L1-regulating axis was demonstrated to promote immune evasion in intrahepatic cholangiocarcinoma by inhibiting the expansion and cytotoxicity of T cells.10 Fang's work highlighted the m6A modification function of ALKBH5 on JAK1 mRNA which leads to the activation of the JAK1-STAT3 pathway, and thus the gastric carcinogenesis. Meanwhile, the work also proposed a comprehensive landscape of the JAK1 mRNA modification process where both long non-coding RNA (lncRNA) and reader protein contributed cooperatively with ALKBH5. Along with the blooming of transcriptome analysis, lncRNAs have emerged as nonnegligible participators in carcinogenesis due to their regulating functions on gene expression and biological processes. LINC00659 is a recently described lncRNA that has been implicated mainly in GC and colorectal cancer (CRC). Studies have revealed that LINC00659 was generated by cancer-associated fibroblasts and then transferred to the cancer cells via exosomes. Functional assays have proved its oncogenic role in promoting CRC cell proliferation, invasion, migration, and epithelial-mesenchymal transition progression via the miR-342-3p/ANXA2 axis.26 YTHDF2 is a noteworthy reader protein that has been proven to be overexpressed in GC tissues and cell lines and involved in gastric carcinogenesis by regulating mRNA metabolism and translation. Functionally speaking, YTHDF2 knockdown could dramatically inhibit the proliferation, migration, and invasion of GC cells.27 But the mechanism of the tumor-promoting mechanism of YTHDF2 remains inconclusive. In Fang's work, LINC00659 was found responsible for the formation of the ALKBH5 complex, which is required for the binding with JAK1 mRNA. And YTHDF2 was identified as indispensable in maintaining JAK1 mRNA stability. These findings enriched the mechanism of the two newly proposed oncogenic factors in GC. The crystal structure of ALKBH5 and its binding pattern with m6A-containing ssRNA has been identified, which enables receptor-based rational drug design approaches for selective inhibitors.28 In fact, several small molecules have been proven to be effective in inhibiting both ALKBH5 and another more frequently studied m6A demethylases, fat mass and obesity-associated protein. Several studies have presented cofactor 2-oxoglutarate (2OG) analogs, like N-oxalylglycine29 and succinate30 as ALKBH5 inhibitors, since the ALKBH5 m6A demethylation activity requires the existence of 2OG. Although the binding ability and patterns of these inhibitors were confirmed by X-ray crystallography and enzyme kinetics studies, there were still concerns about ALKBH5 inhibitors that need to be resolved. Firstly, it is vital to gain a thorough understanding of the underlying mechanisms of ALKBH5 and its heterogeneous regulatory function on downstream effectors in various types of carcinogenesis to avoid potential side effects, especially when works have proved the tumor suppressor role of ALKBH5.13, 22 Meanwhile, currently available ALKBH5 inhibitors are mainly discovered and proved by limited pre-clinical assays. Comprehensive trials on the pharmacokinetic characteristics and latent off-target effects of ALKBH5 await to be conducted before further clinical applications. The authors also acknowledge the technical support from Core Utilities of Cancer Genomics and Pathobiology of the Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong. This work was supported by National Natural Science Foundation of China, Grant Number: 82272990. The authors declare no conflict of interest.